SPOTLIGHT -
Dr. Boughey on Key Results From the ACOSOG Z11102 Trial in Multiple Ipsilateral Breast Cancer
Judy C. Boughey, MD, discusses the significance of results from the phase 2 ACOSOG Z11102 trial evaluating breast conserving therapy in multiple ipsilateral breast cancer.
Read More
Dr. Boughey on Surgical Management of Patients With Node-Positive Breast Cancer
Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses the surgical management of patients with node-positive breast cancer.
Dr. Boughey on Surgery in Patients With HER2+ Breast Cancer
Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses the surgical approach for patients with HER2-positive breast cancer.
Dr. Boughey on Locoregional Trials for Breast Cancer
Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses locoregional clinical trials for breast cancer.
Dr. Boughey Discusses Breast Conservation in Patients with Multiple Ipsilateral Tumors
Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, on breast conservation in patients with multiple ipsilateral tumors.
Dr. Boughey Discusses the Z11 Trial in Breast Cancer
Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses implications for axillary radiation following review of the ACOSOG Z11 trial.
Dr. Boughey on Surgical Resection of Stage IV BC
Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses surgical resection of the primary breast tumor in patients with stage IV breast cancer.
Dr. Boughey on Reducing False Negatives in SLN Surgery
Judy C. Boughey, MD, from the Mayo Clinic in Rochester, MN, discusses surgical techniques examined in the Z1071 study that could help minimize the false negative rates experienced with SLN surgery.
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC